Gufic Biosciences Peer Comparison

NSE: GUFICBIO | BSE: 509079

₹412.20

₹3.75 (0.92%)

As on 27-Aug-2026IST

Market cap

₹4,107 Cr

Revenue (TTM)

₹981 Cr

P/E Ratio

55.9

P/B Ratio

Div. Yield

0 %

Edit

	Gufic Biosciences	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Market cap (₹ Cr)	4,107	21,701	19,356	17,804	18,190
Revenue (₹ Cr)	981	2,570	2,287	2,432	3,230
Net Profit (₹ Cr)	73.45	735.15	678.07	169.62	666.92
Net Margin (%)	7.47	26.88	28.10	6.90	20.60
RoE (%)	11.33	19.16	19.73	20.76	18.75
Price to Earnings	55.90	29.52	29.09	104.97	28.25
Price-To-Book	5.98	4.92	5.14	19.69	4.50

Income Statement (₹ Cr)

	Gufic Biosciences	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Operating Revenue	944.01	2,519.65	1,937.47	2,275.58	2,893.64
Total Income	946.66	2,707.60	2,033.90	2,304.07	2,912.00
Total Expenditure	792.67	1,615.47	1,290.54	2,013.55	1,876.44
EBITDA	151.34	904.18	646.93	262.03	1,017.20
Depreciation	30.83	57.73	65.96	28.58	315.46
EBIT	120.50	846.45	580.97	233.45	701.74
Interest	36.61	9.57	0.61	4.49	231.29
Other Income	2.66	187.95	96.43	28.49	18.36
Exceptional Items	--	-49.16	--	-5.25	--
Profit before Tax	86.55	975.67	676.78	252.20	488.87
Provision for Tax	22.34	253.24	135.69	64.68	114.20
Profit after Tax	64.21	722.43	541.09	187.52	374.67

	Gufic Biosciences	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Shareholder's Funds	664.95	4,202.90	2,850.49	872.79	2,854.36
Minority Interest	0.04	--	35.90	--	417.40
Non-Current Liabilities	159.54	19.19	13.24	394.49	2,100.97
Current Liabilities	517.85	627.48	305.99	1,109.50	1,489.55
Total Liabilities	1,342.37	4,921.88	3,207.85	2,414.58	6,862.28

	Gufic Biosciences	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Non-Current Assets	540.26	1,046.35	1,071.67	509.16	5,531.13
Current Assets	802.12	3,803.22	2,133.95	1,859.88	1,331.15
Total Assets	1,342.37	4,921.88	3,207.85	2,414.58	6,862.28
Total Debt*	385.16	2.50	0.55	0.00	2,421.66
Net Current Assets	284.27	3,175.74	1,827.96	750.38	-158.40
Contingent Liabilities	11.70	370.49	0.64	121.23	64.29

	Gufic Biosciences	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Cash From Operating Activities	45.14	967.57	432.37	-15.14	1,065.01
Cash Flow from Investing Activities	-30.96	-561.67	-334.73	18.69	-79.97
Cash from Financing Activities	32.29	-798.31	-38.32	-91.97	-881.32
Net Cash Inflow / Outflow	46.46	-392.41	59.32	-88.42	103.72

	Gufic Biosciences	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
ROCE (%)	12.56	23.39	26.22	31.24	13.59
ROE (%)	10.14	17.16	21.72	23.02	13.81
ROA (%)	5.11	14.91	18.37	8.90	5.48
EBIT Margin (%)	16.31	43.34	38.37	12.77	35.79
Net Margin (%)	6.78	26.68	26.60	8.14	12.87
Cash Profit Margin (%)	7.78	29.72	31.33	9.47	23.22

	Gufic Biosciences	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Revenue Growth (%)	15.15	10.45	14.37	32.59	44.02
EBIT Growth (%)	10.21	19.68	20.21	-1.38	48.22
Net Profit Growth (%)	-7.81	-5.88	17.27	62.02	-5.65
EPS Growth (%)	-7.81	-5.88	17.25	62.02	-10.39
Book Value Growth (%)	10.65	-0.34	23.77	13.51	10.19

	Gufic Biosciences	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Price / Earnings	42.88	29.89	28.38	103.45	54.83
Price / Book Value	4.14	5.14	5.52	22.39	6.78
Dividend Yield (%)	0.04	1.59	0.30	0.46	0.52
EV/EBITDA	19.89	16.93	19.78	65.23	20.75
Market Cap (₹ Cr)	2,753.29	21,592.90	15,219.80	19,398.64	19,292.77

	Gufic Biosciences	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debt to Equity	0.58	0.00	0.00	0.00	0.85
Short term debt to equity ratio	0.38	0.00	0.00	--	0.14
Current Ratio	1.55	6.06	6.97	1.68	0.89
Quick Ratio	0.92	5.31	5.88	0.75	0.67
Interest Coverage	3.36	102.95	1,110.48	57.17	3.11

	Gufic Biosciences	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debtors to sales (%)	31.50	7.22	32.65	9.39	15.85
Asset Turnover	0.97	0.54	0.66	1.08	0.43
Receivable days	91.39	26.06	110.70	31.88	54.07
Inventory Days	80.84	65.95	65.86	126.03	32.16
Payable days	187.06	81.01	105.88	163.79	140.91
Cash Conversion Cycle	-14.82	11.00	70.68	-5.88	-54.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.